Atara Biotherapeutics, Inc.
A biotechnology company making "off-the-shelf" T-cell therapies that treat cancer, autoimmune diseases, and viral infections, using cells donated by healthy strangers rather than a patient's own cells—so treatment can be delivered in days instead of weeks. Founded in 2012 by Dr. Isaac Ciechanover, the company is named in memory of his mother, Atara, who died of ovarian cancer; the name means "crown" in Hebrew. The technology grew out of research at Memorial Sloan Kettering Cancer Center and Australia's QIMR Berghofer Medical Research Institute.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13G/APassive | 7.6% | 687.7K | Aug 14, 2026 |
| Point72 Capital Advisors, Inc. | 13G/APassive | 7.6% | 687.7K | Aug 14, 2026 |
| Steven A. Cohen | 13G/APassive | 7.6% | 687.7K | Aug 14, 2026 |
| Redmile Group, LLC | 13D/AActivist | 9.9% | 951.0K | Jul 24, 2026 |
| Green Jeremy | 13D/AActivist | 9.9% | 951.0K | Jul 24, 2026 |
| Redmile Biopharma Investments II, L.P. | 13D/AActivist | 6.6% | 631.0K | Jul 24, 2026 |
| Redmile Strategic Long Only Trading Sub, Ltd. | 13D/AActivist | 4.2% | 401.9K | Jul 24, 2026 |
| Adage Capital Management, L.P. | 13GPassive | 8.56% | 700.0K | May 13, 2026 |
| Robert Atchinson | 13GPassive | 8.56% | 700.0K | May 13, 2026 |
| Phillip Gross | 13GPassive | 8.56% | 700.0K | May 13, 2026 |